Last updated: April 23, 2026
Who Supplies Injectafer (Ferric Carboxymaltose): Manufacturers and Input-Chemical Sources
What company manufactures Injectafer?
Injectafer (ferric carboxymaltose) is supplied to the market by Vifor Pharma (brand owner and commercialization entity in many regions). The product is manufactured for Vifor under contract manufacturing arrangements tied to the company’s global supply chain.
Which manufacturing network supports Injectafer supply?
Public-facing documentation for Injectafer supply is largely handled through:
- Vifor Pharma’s global supply chain (brand owner and distributor of record in multiple markets)
- Contract manufacturing organizations (CMOs) producing ferric carboxymaltose bulk drug substance and drug product to Vifor specifications
Drug-substance and finished-product manufacturer names can vary by jurisdiction, packaging, and regulatory filing status; the most reliable attribution for “who supplies” is therefore the brand owner/distributor of record for each market and packaging configuration.
Are there multiple supply sources for Injectafer batches?
Yes. For parenteral iron products, batch supply typically relies on a multi-site manufacturing strategy to manage continuity of supply and regulatory compliance. In practice, this means different lots can trace to:
- different manufacturing sites for drug substance and/or drug product
- different packaging sites
- different regional distribution partners
What raw-material or input suppliers support the product?
Injectafer contains ferric carboxymaltose formulated for intravenous administration. Supplier mapping for the underlying inputs (metal salt, carboxymaltose polymer components, excipients, and sterile manufacture consumables) is typically documented in:
- regulatory chemistry and manufacturing controls (CMC) sections for each dossier/market
- quality agreements between Vifor and CMOs
- procurement records held by the manufacturing network
Public procurement-level naming of every input supplier is not consistently disclosed in open sources.
How to interpret “suppliers” for investment or procurement decisions
For a business decision, “suppliers” for Injectafer are best treated as two layers:
| Supplier layer |
What it covers |
Where it appears in practice |
| Brand owner / distributor of record |
Commercial supply responsibility, market release, order fulfillment |
Product label, wholesaler channels, market authorization holder listings |
| CMOs / manufacturing sites |
Bulk drug substance and finished sterile drug product manufacturing |
Batch release documentation, national regulatory filings, manufacturer-of-record sections |
Market supply reality for Injectafer
Injectafer is a specialty, sterile injectable. Lead times and allocation pressure often track:
- sterile fill-finish capacity
- batch release and stability testing throughput
- availability of drug substance and key excipients under cGMP controls
Key Takeaways
- Vifor Pharma is the commercial supplier / brand owner of Injectafer across major markets.
- Injectafer supply depends on a contract manufacturing network for drug substance and finished sterile product; site-level identities vary by jurisdiction and packaging configuration.
- Open-source material generally does not enumerate every upstream chemical or consumable supplier tied to ferric carboxymaltose and sterile manufacturing.
FAQs
-
Who is the supplier of Injectafer?
Vifor Pharma is the brand owner and the commercial supplier/distributor of record in many markets.
-
Who manufactures Injectafer?
Injectafer is produced via Vifor’s contract manufacturing network; specific manufacturing site names can differ by regulatory filing and region.
-
Are there alternative sources for Injectafer manufacturing?
Supply continuity is typically supported by multiple manufacturing sites and packaging partners within the contracted network.
-
Can I identify suppliers of raw materials like carboxymaltose components publicly?
Upstream input suppliers are not consistently disclosed in public-facing materials; mapping usually requires CMC dossier access and supplier disclosures under quality agreements.
-
What matters most for supply risk in Injectafer?
The main drivers are sterile manufacturing capacity, batch release throughput, and drug-substance availability under cGMP controls.
References
[1] Vifor Pharma. Injectafer (ferric carboxymaltose) product information and brand materials. (Accessed via official brand channels)
[2] European Medicines Agency (EMA). Assessment history and public product information for ferric carboxymaltose (Injectafer, where applicable). APA accessed from EMA public pages.
[3] U.S. Food and Drug Administration (FDA). Product labeling for Injectafer (ferric carboxymaltose) and associated manufacturer/distributor sections. APA accessed from FDA label database.
